Evidence map›Paper›PMID 42770002›Full record

ArticleAdvances in pharmacological and pharmaceutical sciences2026

Neuroprotective Effects of Huperzine B and

Kittikun Viwatpinyo, Poommaree Namchaiw, Pipob Suwanchaikasem, Sujira Mukda, Sudichhya Tamrakar, Amit Jaisi, Sakan Warinhomhoun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in pharmacological and pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kittikun ViwatpinyoSchool of Medicine, Walailak University, Thai Buri Nakhon Si Thammarat, 80160, Thailand, wu.ac.th.ORCID https://orcid.org/0000-0003-1802-023X
Poommaree NamchaiwBiological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, Thailand, kmutt.ac.th.ORCID https://orcid.org/0000-0003-0275-6234
Pipob SuwanchaikasemBaiya Phytopharm Co., Ltd., Chulalongkorn University, Bangkok 10330, Thailand, chula.ac.th.ORCID https://orcid.org/0000-0001-7991-6414
Sujira MukdaResearch Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakorn Pathom 73170, Thailand, mahidol.ac.th.ORCID https://orcid.org/0000-0002-9646-2394
Sudichhya TamrakarResearch Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakorn Pathom 73170, Thailand, mahidol.ac.th.ORCID https://orcid.org/0000-0001-8755-0520
Amit JaisiSchool of Pharmacy, Walailak University, Thasala Nakhon Si Thammarat, 80160, Thailand, wu.ac.th.ORCID https://orcid.org/0000-0003-0261-7170
Sakan WarinhomhounCollege of Oriental Medicine, Rangsit University, Pathum Thani 12000, Thailand, rsu.ac.th.ORCID https://orcid.org/0000-0003-0299-6975

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder associated with dopaminergic neuronal loss, mitochondrial dysfunction, and redox imbalance. Huperzine B (HupB), an alkaloid derived from

Indexed as

Huperzia carinatahuperzine Boxidative stressParkinson’s diseaseSH-SY5Y cells

Identifiers

PMID42770002
PMCPMC13591997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.